Rituxumab Combined With Chemotherapy (PVB) For Poor Prognosis HIV-Related Non-Hodgkin's Lymphoma
- Determine the response rate of patients with poor-prognosis, HIV-related non-Hodgkin's
lymphoma treated with rituximab combined with prednisolone, vincristine, and bleomycin.
- Determine the toxicity of this regimen in these patients.
- Determine the time to progression and survival of patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive chemotherapy comprising vincristine IV and bleomycin IV on day 1 and oral
prednisolone every other day beginning on day 1. Treatment repeats every 3 weeks for 6
courses. Patients also receive rituximab on days 14, 21, 28, and 35. Patients who achieve
complete response (CR) receive 2 additional courses of chemotherapy after CR.
Patients are followed every 1-2 months.
PROJECTED ACCRUAL: A total of 10-20 patients will be accrued for this study.
Primary Purpose: Treatment
Ruth Pettengell, MD
St. George's Hospital
United States: Federal Government